BETR — BetterLife Pharma Share Price
0.000.00%
Last trade - 00:00- CA$11.65m
- CA$15.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be self-administered. Its synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and is based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. It also owns a drug candidate for the treatment of viral infections.
Directors
- Ahmad Doroudian CHM (57)
- Moira Ong CFO (44)
- Hooshmand Sheshbaradaran OTH
- Robert Metcalfe IND
- Ralph Pullen IND
- Wolfgang Renz IND (52)
- Last Annual
- January 31st, 2024
- Last Interim
- October 31st, 2024
- Incorporated
- June 10th, 2002
- Public Since
- December 19th, 2017
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 129,473,385
- Address
- 1275 WEST 6TH AVENUE, VANCOUVER, V6H 1A6
- Web
- https://abetterlifepharma.com/
- Phone
- +1 4388848841
- Auditors
- MNP LLP
Upcoming Events for BETR
BetterLife Pharma Inc Annual Shareholders Meeting
Q1 2026 BetterLife Pharma Inc Earnings Release
Q2 2026 BetterLife Pharma Inc Earnings Release
Similar to BETR
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BioMark Diagnostics
Canadian Securities Exchange
FAQ
What is the BetterLife Pharma share price?
As of Today at 19:34 UTC, shares in BetterLife Pharma are trading at CA$0.09. This share price information is delayed by 15 minutes.
How has the BetterLife Pharma share price performed this year?
Shares in BetterLife Pharma last closed at CA$0.09 and the price had moved by -10% over the past 365 days. In terms of relative price strength the BetterLife Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -18.87% over the past year.
What are the analyst and broker recommendations for BetterLife Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the BetterLife Pharma dividend yield?
BetterLife Pharma does not currently pay a dividend.
Does BetterLife Pharma pay a dividend?
BetterLife Pharma does not currently pay a dividend.
When does BetterLife Pharma next pay dividends?
BetterLife Pharma does not currently pay a dividend.
How do I buy BetterLife Pharma shares?
To buy shares in BetterLife Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BetterLife Pharma?
As of the previous close price of CA$0.09, shares in BetterLife Pharma had a market capitalisation of CA$11.65m.
Where are BetterLife Pharma shares listed?
Here are the trading details for BetterLife Pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BETR
What kind of share is BetterLife Pharma?
Based on an overall assessment of its quality, value and momentum BetterLife Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BetterLife Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the BetterLife Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BetterLife Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -20.02%.
As of the last closing price of CA$0.09, shares in BetterLife Pharma were trading -24.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BetterLife Pharma PE Ratio?
The BetterLife Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BetterLife Pharma?
BetterLife Pharma's management team is headed by:
- Ahmad Doroudian - CHM
- Moira Ong - CFO
- Hooshmand Sheshbaradaran - OTH
- Robert Metcalfe - IND
- Ralph Pullen - IND
- Wolfgang Renz - IND